Poly Medicure Q2 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Poly Medicure management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Poly Medicure management said on order book — free account, 30 seconds.
Capex plans
Track Poly Medicure — get its next earnings analysis in your feed
Margin guidance
Order book
How does Poly Medicure rank vs peers in Healthcare Equipment & Supplies?
Pro featureHow does Poly Medicure rank in Healthcare Equipment & Supplies?
Compare Poly Medicure against every Healthcare Equipment & Supplies company (Q2 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Poly Medicure's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Healthcare Equipment & Supplies this season
- QMS Medical (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
- Tarsons Products (Q2 FY26)
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…
- Vaidya Sane (Q2 FY26)
Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…